BioSpace News Archive

Partnership with M.I. Tech Brings Strategic Roll-Out of Globally Recognized Medical Products to the U.S. Market

Dr. Jene will lead the efforts to add healthcare assets to PDL’s portfolio of products and companies.

The Department of Ear Nose & Throat/Allergy at Summit Medical Group was part of a clinical trial that led the U.S. Food & Drug Administration (FDA) to approve XHANCE™ (fluticasone proprionate), a nasal spray for the treatment of nasal polyps in patients 18 years of age or older.

Results showed DUPIXENT demonstrated a significant improvement in multiple asthma endpoints in two Phase 3 clinical trials.

Breckenridge Pharmaceutical, Inc. announced today the supplemental approval for the 40mg strength of Duloxetine Delayed-Release Capsules.

GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (Paris:SIGHT), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that it will host a KOL Event on June 12, 2018 in New York City from 8 a.m. – 10:30 a.m. ET.

Sofinnova Partners significantly reinforces its team with an internationally renowned physician and entrepreneur

Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) today announced that full results from HAVEN 3 study (NCT02847637) and HAVEN 4 study (NCT03020160) evaluating Chugai’s hemophilia A treatment HEMLIBRA® [generic name: emicizumab (genetical recombination)] are being presented at the World Federation of Hemophilia 2018 World Congress held in Glasgow, Scotland from May 20 to 24

Dolutegravir/rilpivirine, the result of a collaboration with ViiV Healthcare, offers a complete daily treatment regimen for virologically suppressed adults living with HIV-1 in a single-pill

Dr. Chris Yu, Chief Executive Officer of international life sciences corporation Anpac Bio-Medical Science Company, confirmed the company’s 2018 revenue vaulted nearly 300%.